Literature DB >> 28990585

The diverse functions of the PD1 inhibitory pathway.

Arlene H Sharpe1, Kristen E Pauken1.   

Abstract

T cell activation is a highly regulated process involving peptide-MHC engagement of the T cell receptor and positive costimulatory signals. Upon activation, coinhibitory 'checkpoints', including programmed cell death protein 1 (PD1), become induced to regulate T cells. PD1 has an essential role in balancing protective immunity and immunopathology, homeostasis and tolerance. However, during responses to chronic pathogens and tumours, PD1 expression can limit protective immunity. Recently developed PD1 pathway inhibitors have revolutionized cancer treatment for some patients, but the majority of patients do not show complete responses, and adverse events have been noted. This Review discusses the diverse roles of the PD1 pathway in regulating immune responses and how this knowledge can improve cancer immunotherapy as well as restore and/or maintain tolerance during autoimmunity and transplantation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28990585     DOI: 10.1038/nri.2017.108

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  169 in total

1.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

2.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

5.  Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1.

Authors:  Shinichiro Fuse; Ching-Yi Tsai; Michael J Molloy; S Rameeza Allie; Weijun Zhang; Hideo Yagita; Edward J Usherwood
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

6.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

7.  A link between PDL1 and T regulatory cells in fetomaternal tolerance.

Authors:  Antje Habicht; Shirine Dada; Mollie Jurewicz; Brian T Fife; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Indira Guleria
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

8.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

9.  Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.

Authors:  Helge Frebel; Veronika Nindl; Reto A Schuepbach; Thomas Braunschweiler; Kirsten Richter; Johannes Vogel; Carsten A Wagner; Dominique Loffing-Cueni; Michael Kurrer; Burkhard Ludewig; Annette Oxenius
Journal:  J Exp Med       Date:  2012-12-10       Impact factor: 14.307

10.  Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.

Authors:  Alison Taylor; James A Harker; Kittiphat Chanthong; Philip G Stevenson; Elina I Zuniga; Christopher E Rudd
Journal:  Immunity       Date:  2016-02-16       Impact factor: 31.745

View more
  437 in total

Review 1.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

Review 2.  Immunotherapy and predictive immunologic profile: the tip of the iceberg.

Authors:  Tatiana Cunha Pereira; Paulo Rodrigues-Santos; Jani Sofia Almeida; Fábio Rêgo Salgueiro; Ana Raquel Monteiro; Filipa Macedo; Rita Félix Soares; Isabel Domingues; Paula Jacinto; Gabriela Sousa
Journal:  Med Oncol       Date:  2021-03-31       Impact factor: 3.064

3.  Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.

Authors:  Tao Fan; Yu Liu; Hengchang Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Fengwei Tan; Qi Xue; Shungeng Gao; Chunxiang Li; Jie He
Journal:  Cancer Immunol Immunother       Date:  2021-05-11       Impact factor: 6.968

Review 4.  [Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Authors:  Matthias Totzeck; Tienush Rassaf
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

5.  Dysregulation of the PD-1/PD-L1 pathway contributes to the pathogenesis of celiac disease.

Authors:  Candelaria Ponce de León; Miguel Angel López-Casado; Pedro Lorite; Teresa Palomeque; María Isabel Torres
Journal:  Cell Mol Immunol       Date:  2019-06-26       Impact factor: 11.530

6.  Cellular therapy against public neoantigens.

Authors:  Paul M Armistead
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

Review 7.  Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.

Authors:  Kristen E Pauken; Michael Dougan; Noel R Rose; Andrew H Lichtman; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2019-04-30       Impact factor: 16.687

Review 8.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

Review 9.  Heart failure in cancer: role of checkpoint inhibitors.

Authors:  Murilo Delgobo; Stefan Frantz
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 10.  Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Authors:  Jinfang Zhang; Fabin Dang; Junming Ren; Wenyi Wei
Journal:  Trends Biochem Sci       Date:  2018-10-01       Impact factor: 13.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.